{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:42:13Z","timestamp":1790743333788,"version":"4.1.0"},"reference-count":18,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:p>\n            The\n            <jats:italic>in vitro<\/jats:italic>\n            activities of rifampin, rifabutin, rifapentine, and rifaximin were tested against 200 periprosthetic joint infection (PJI)-associated staphylococci. Seven rifampin-resistant isolates had MICs of \u22654\u2009\u03bcg\/ml. Three isolates had rifampin MICs of 0.25 to 1 \u03bcg\/ml and harbored an Asp471Gly RpoB variant, suggesting that the CLSI rifampin-susceptible staphylococcal breakpoint of \u22641 \u03bcg\/ml may be too high.\n          <\/jats:p>","DOI":"10.1128\/aac.00959-19","type":"journal-article","created":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T12:09:42Z","timestamp":1566562182000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":39,"title":["<i>In Vitro<\/i>\n            Activity of Rifampin, Rifabutin, Rifapentine, and Rifaximin against Planktonic and Biofilm States of Staphylococci Isolated from Periprosthetic Joint Infection"],"prefix":"10.1128","volume":"63","author":[{"given":"Mariana","family":"Albano","sequence":"first","affiliation":[{"name":"Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa J.","family":"Karau","sequence":"additional","affiliation":[{"name":"Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerryl E.","family":"Greenwood-Quaintance","sequence":"additional","affiliation":[{"name":"Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas R.","family":"Osmon","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA"},{"name":"Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin P.","family":"Oravec","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Berry","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Abdel","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6344-4141","authenticated-orcid":false,"given":"Robin","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA"},{"name":"Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis803"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00111-13"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.10.56"},{"key":"e_1_3_3_5_2","first-page":"207","article-title":"Staphylococcal biofilms","volume":"322","author":"Otto M","year":"2008","unstructured":"Otto M. 2008. Staphylococcal biofilms. Curr Top Microbiol Immunol 322:207\u2013228.","journal-title":"Curr Top Microbiol Immunol"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2006.08.003"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.46.3.900-903.2002"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2010.02.001"},{"key":"e_1_3_3_9_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. CLSI standard M07","author":"CLSI","year":"2018","unstructured":"CLSI. 2018. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. CLSI standard M07, 11th ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"11"},{"key":"e_1_3_3_10_2","volume-title":"Performance standards for antimicrobial susceptibility testing. CLSI supplement M100","author":"CLSI","year":"2019","unstructured":"CLSI. 2019. Performance standards for antimicrobial susceptibility testing. CLSI supplement M100, 29th ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"29"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.27.4.615"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.10.2590"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.12.019"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05078-14"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/47.2.153"},{"key":"e_1_3_3_16_2","unstructured":"EUCAST. 2019. Antimicrobial wild type distributions of microorganisms. European Committee on Antimicrobial Susceptibility Testing (EUCAST). https:\/\/mic.eucast.org\/Eucast2\/SearchController\/search.jsp?action=performSearch&BeginIndex=0&Micdif=mic&NumberIndex=50&Antib=242&Specium=-1."},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.11.2813"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2016.01.008"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11999-015-4300-3"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00959-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00959-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:26:30Z","timestamp":1645478790000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00959-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["10.1128\/AAC.00959-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.00959-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"2019-06-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00959-19"}}